According to a new paper published in Nature Biotechnology lipid nanoparticles (LNPs) don’t stay in the injection site — they circulate throughout the entire body and reach vital organs, including the heart.
The findings;
suggest a potential mechanism by which LNP-based mRNA vaccines could contribute to the reported cardiac complications [including myocarditis]
Now published in one of the top scientific journals, the study’s findings contradict claims by public health officials and scientists during the COVID-19 vaccine rollouts that the LNPs were safe because they travelled only to specific targeted sites in the body.
The authors said there is no existing technology good enough to trace where LNPs end up in the body after they are administered via intramuscular injection — especially for medication like vaccines, which contain low doses of the particles.
In this study the authors developed an experimental technology to trace where different carriers of nanoparticles, including LNPs, end up in the body after intramuscular injection which they tested in mice.
In the mice the researchers found that even at extremely low doses, LNPs carrying the SARS-CoV-2 spike protein mRNA reached vital organs, such as heart tissue and caused cellular or tissue changes.
Nicolas Hulscher, epidemiologist and McCullough Foundation administrator, wrote on Substack ;
COVID-19 mRNA injection LNPs systemically circulate and are taken up into vital organ systems resulting in body-wide toxic Spike protein production
The idea that the LNP stayed in the muscle was perpetuated by major publications, like Science and Open Forum Infectious Diseases — a journal funded in part by the Centers for Disease Control and Prevention and Pfizer — even though Pfizer’s own study showed that after just 8 hours, a mere 22% of the initially injected LNPs remain at the site of injection, 18% migrated to the liver and 1% migrated to the spleen.
According to the study, there are over 30 new drugs — including genome editing tools, mRNA and protein drugs — approved by the U.S. Food and Drug Administration and the European Medicines Agency to treat disease. However, drug developers face a major challenge in the clinical application of these tools — how to ensure that the drugs reach only the cells they are targeting.
Nanocarriers, like LNP, are designed with a coating to make them stable and help them reach their target cells. However, when they are introduced into the body, they change in ways that make their intended functionality more unpredictable.
The major limitation of the Single Cell Precision Nanocarrier Identification technology is that it cannot be used in living subjects. That means there is still no way to effectively track where LNPs go in living humans.
Their technology uses machine learning to analyze image data — making it possible to precisely quantify where the nanoparticles go at the organ, tissue and single-cell level across the entire body.
They specifically designed it to measure the low doses of the medications that are usually present in vaccines. Then they tested it on several different new types of drugs and were able to successfully identify where the nanoparticles went across a mouse’s entire body.
After an LNP containing the SARS-CoV-2 spike protein mRNA was injected into the muscle, the researchers detected the mRNA and spike protein in the mice’s liver, spleen, lungs, heart, head and kidneys.
The study’s authors said further research is needed to determine whether similar effects occur in humans and whether the molecular changes they found across the mice’s bodies are linked to clinical symptoms.
They rushed in these so-called vaccines using experimental technology without fundamental safety work. There is a decades long process for a reason. These need to be pulled from market immediately.